What are the chances of surviving nasopharyngeal cancer?
If the cancer is located only in the nasopharynx, the 5-year survival rate is 85%. If the cancer has spread to nearby tissues or organs and/or regional lymph nodes, the 5-year survival rate is 71%. If there is distant spread to other parts of the body, the 5-year survival rate is 49%.
Does nasopharyngeal cancer come back?
Survivors of nasopharyngeal cancer (NPC) can get any second cancer, but they have an increased risk of: Cancer of the tongue. Cancer of the nose and nasal cavity.
Can nasopharyngeal cancer be cured?
Many cancers of the nasopharynx can be cured, especially if they are found early. Descriptions of the common types of treatments used for NPC are listed below. Your care plan may also include treatment for symptoms and side effects, an important part of cancer care.
Can I live with nasopharyngeal cancer?
For all people diagnosed with nasopharyngeal cancer in England and Ireland: almost 75 out of 100 people (almost 75%) will survive their cancer for 1 year after diagnosis. around 50 out of 100 people (50%) will survive their cancer for 5 years or more after they are diagnosed.
How long do you live with nasopharyngeal cancer?
Survival rates can give you an idea of what percentage of people with the same type and stage of cancer are still alive a certain amount of time (usually 5 years) after they were diagnosed….5-year relative survival rates for nasopharyngeal cancer.
| SEER stage | 5-year relative survival rate |
|---|---|
| All SEER stages combined | 62% |
How serious is nasopharyngeal cancer?
The outlook for nasopharyngeal cancer depends on your age, general health and how advanced the condition is when you’re diagnosed. Radiotherapy can often cure very early-stage nasopharyngeal cancer. But it’s sometimes diagnosed at a more advanced stage because it doesn’t always cause obvious symptoms until later on.
How long can you have nasopharyngeal cancer?
Is Nimotuzumab only for nasopharyngeal cancer?
Since it was approved in China for the treatment of nasopharyngeal cancer (NPC), it has been widely used in NPC and in many clinical trials for other cancer types. However, the optimal dose and administration frequency of nimotuzumab that should be used and which kind of cancer patients will be more benefited from nimotuzumab is still unknown.
Can nimotuzumab and Gemzar improve survival in pancreatic cancer?
The addition of nimotuzumab to gemcitabine (Gemzar®) increases overall survival in patients with K-Ras wild-type advanced pancreatic cancer, particularly for patients who did not need surgery for Nimotuzumab Significantly Improves Overall Survival for K-Ras Wild-Type Advanced Pancreatic Cancer | ASCO
What is the survival rate of nimotuzumab-gemcitabine?
The one-year survival rate was 43.6% in the nimotuzumab-gemcitabine group vs. 26.8% in the placebo-gemcitabine group; the three-year survival rate was 13.9% vs. 2.7%, respectively. The median progression-free survival (PFS) was 4.2 months in the nimotuzumab-gemcitabine group vs. 3.6 months in the placebo-gemcitabine group.
When was Nimotuzumab approved in China?
The drug, developed as a joint Chinese-Cuban venture, was approved by the Chinese National Medical Products Administration to be marketed in China in 2008 for the treatment of nasopharyngeal carcinoma. A series of clinical studies of nimotuzumab for head and neck, cervical, esophageal, and other cancers are ongoing in China.